Search Results

There are 30149 results for: content related to: The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

  1. You have free access to this content
    HCV Therapeutics: Approved Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26880

  2. You have free access to this content
    AASLD Abstracts

    Hepatology

    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Version of Record online : 1 OCT 2012, DOI: 10.1002/hep.26040

  3. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin

    Journal of Viral Hepatitis

    Volume 14, Issue 6, June 2007, Pages: 396–403, Y. Asahina, N. Izumi, N. Umeda, T. Hosokawa, K. Ueda, F. Doi, K. Tsuchiya, H. Nakanishi, K. Matsunaga, T. Kitamura, M. Kurosaki, M. Uchihara, M. Higaki and S. Miyake

    Version of Record online : 25 AUG 2006, DOI: 10.1111/j.1365-2893.2006.00803.x

  4. You have free access to this content
    British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013

    HIV Medicine

    Volume 14, Issue S4, November 2013, Pages: 1–71, Writing Group, Dr Ed Wilkins, Dr Mark Nelson, Dr Kosh Agarwal, Ms Dola Awoyemi, Dr Eleanor Barnes, Dr Sanjay Bhagani, Dr Gary Brook, Dr Ashley Brown, Ms Sheena Castelino, Dr Graham Cooke, Prof Martin Fisher, Prof Anna Maria Geretti, Mr Robert James, Dr Ranjababu Kulasegaram, Prof Clifford Leen, Prof David Mutimer, Dr Chloe Orkin, Dr Emma Page, Dr Adrian Palfreeman, Dr Padmasayee Papineni, Dr Alison Rodger and Dr CY William Tong

    Version of Record online : 25 OCT 2013, DOI: 10.1111/hiv.12106

  5. You have free access to this content
    Abstracts 210 to 431

    Hepatology

    Volume 46, Issue S1, October 2007, Pages: 331A–430A,

    Version of Record online : 19 SEP 2007, DOI: 10.1002/hep.22017

  6. You have free access to this content
    Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin

    Hepatology

    Volume 59, Issue 6, June 2014, Pages: 2101–2109, Teresa Santantonio, Massimo Fasano, Evangelista Sagnelli, Paolo Tundo, Sergio Babudieri, Paolo Fabris, Mario Toti, Giovanni Di Perri, Nicoletta Marino, Eligio Pizzigallo, Gioacchino Angarano and the Acute Hepatitis C Study Group

    Version of Record online : 29 APR 2014, DOI: 10.1002/hep.26991

  7. You have free access to this content
    Abstracts 1020 to 1278

    Hepatology

    Volume 42, Issue S1, October 2005, Pages: 598A–702A,

    Version of Record online : 5 OCT 2005, DOI: 10.1002/hep.20927

  8. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group

    Journal of Gastroenterology and Hepatology

    Volume 23, Issue 7pt1, July 2008, Pages: 1094–1104, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Akihide Masumoto, Toshihiro Maruyama, Makoto Nakamuta, Munechika Enjoji, Koichi Azuma, Junya Shimono, Hironori Sakai, Shinji Shimoda, Jun Hayashi and Kyushu University Liver Disease Study (KULDS) Group

    Version of Record online : 3 FEB 2008, DOI: 10.1111/j.1440-1746.2008.05319.x

  9. Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C

    Journal of Viral Hepatitis

    Volume 17, Issue 6, June 2010, Pages: 410–418, S. S. Tan, M. R. Abu Hassan, A. Abdullah, B. P. Ooi, T. Korompis and M. I. Merican

    Version of Record online : 16 SEP 2009, DOI: 10.1111/j.1365-2893.2009.01191.x

  10. Hepatitis C

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 15 SEP 2006, DOI: 10.1002/9780470041000.cedt033

  11. You have free access to this content
    Hepatitis C virus: How genetic variability affects pathobiology of disease

    Journal of Gastroenterology and Hepatology

    Volume 26, Issue s1, January 2011, Pages: 83–95, Kazuaki Chayama and C Nelson Hayes

    Version of Record online : 4 JAN 2011, DOI: 10.1111/j.1440-1746.2010.06550.x

  12. Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin

    Journal of Viral Hepatitis

    Volume 16, Issue 8, August 2009, Pages: 578–585, T. Oze, N. Hiramatsu, T. Yakushijin, M. Kurokawa, T. Igura, K. Mochizuki, K. Imanaka, A. Yamada, M. Oshita, H. Hagiwara, E. Mita, T. Ito, Y. Inui, T. Hijioka, S. Tamura, H. Yoshihara, E. Hayashi, A. Inoue, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara and N. Hayashi

    Version of Record online : 22 JUN 2009, DOI: 10.1111/j.1365-2893.2009.01116.x

  13. You have free access to this content
    Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Goran Hauser, Tahany Awad, Jesper Brok, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk, Christian Gluud and Lise Lotte Gluud

    Published Online : 28 FEB 2014, DOI: 10.1002/14651858.CD005441.pub3

  14. You have free access to this content
    Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Goran Hauser, Tahany Awad, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk and Christian Gluud

    Published Online : 28 FEB 2014, DOI: 10.1002/14651858.CD005642.pub3

  15. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

    Journal of Viral Hepatitis

    Volume 16, Issue 8, August 2009, Pages: 586–594, N. Hiramatsu, T. Oze, T. Yakushijin, Y. Inoue, T. Igura, K. Mochizuki, K. Imanaka, A. Kaneko, M. Oshita, H. Hagiwara, E. Mita, T. Nagase, T. Ito, Y. Inui, T. Hijioka, K. Katayama, S. Tamura, H. Yoshihara, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara and N. Hayashi

    Version of Record online : 22 JUN 2009, DOI: 10.1111/j.1365-2893.2009.01106.x

  16. You have free access to this content
    Pegylated Interferon Alpha-2b for Patients with HCV Recurrence and Graft Fibrosis Following Liver Transplantation

    American Journal of Transplantation

    Volume 6, Issue 4, April 2006, Pages: 825–833, M. Heydtmann, D. Freshwater, T. Dudley, V. Lai, S. Palmer, S. Hübscher and D. Mutimer

    Version of Record online : 21 FEB 2006, DOI: 10.1111/j.1600-6143.2006.01255.x

  17. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

    Hepatology Research

    Volume 40, Issue 4, April 2010, Pages: 347–368, Izumi Namiki, Shuhei Nishiguchi, Keisuke Hino, Fumitaka Suzuki, Hiromitsu Kumada, Yoshihito Itoh, Yusuhiro Asahina, Akihiro Tamori, Naoki Hiramatsu, Norio Hayashi and Masatoshi Kudo

    Version of Record online : 29 MAR 2010, DOI: 10.1111/j.1872-034X.2010.00642.x

  18. You have free access to this content
    AASLD Abstracts 1143–1352

    Hepatology

    Volume 48, Issue S1, October 2008, Pages: 817A–911A,

    Version of Record online : 24 SEP 2008, DOI: 10.1002/hep.22645

  19. Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation

    Hepatology Research

    Volume 41, Issue 12, December 2011, Pages: 1137–1144, Hideyuki Tamai, Naoki Shingaki, Tatsuya Shiraki, Hiroshi Tukuda, Yoshiyuki Mori, Kosaku Moribata, Shotaro Enomoto, Hisanobu Deguchi, Kazuki Ueda, Izumi Inoue, Takao Maekita, Mikitaka Iguchi, Kimihiko Yanaoka, Masashi Oka and Masao Ichinose

    Version of Record online : 26 SEP 2011, DOI: 10.1111/j.1872-034X.2011.00879.x

  20. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study

    Journal of Gastroenterology and Hepatology

    Volume 27, Issue 7, July 2012, Pages: 1233–1240, Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi and The Kyushu University Liver Disease Study [KULDS] Group

    Version of Record online : 19 JUN 2012, DOI: 10.1111/j.1440-1746.2011.06965.x